Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32229257    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32229257  :  Publisher
PDF vom PMID32229257 :   free
PDF vom PMID32229257

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Risk-adapted Treatment Strategy For COVID-19 Patients #MMPMID32229257
  • Zheng C; Wang J; Guo H; Lu Z; Ma Y; Zhu Y; Xia D; Wang Y; He H; Zhou J; Wang Y; Fei M; Yin Y; Zheng M; Xu Y
  • Int J Infect Dis 2020[May]; 94 (ä): 74-77 PMID32229257show ga
  • BACKGROUND: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. METHODS: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. RESULTS: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n=34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p=0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p=0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p=0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. CONCLUSIONS: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production.
  • |*Betacoronavirus[MESH]
  • |Adaptation, Physiological[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |Coronavirus Infections/*therapy[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*therapy[MESH]
  • |Risk Factors[MESH]
  • |Tomography, X-Ray Computed[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    74 ä.94 2020